Intracellular calcium signalling in Alzheimer's disease

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 1-2, 2010, Pages 30-41

  Hermes, Marina ^a   Eichhoff, Gerhard ^a   Garaschuk, Olga ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Calcium dyshomeostasis; Hyperactivity; In vivo calcium imaging; Plaque vicinity; Seizure; Two photon microscopy

Indexed keywords

AMYLOID BETA PROTEIN; CALCIUM; ISOPROTEIN; PRESENILIN;

ALZHEIMER DISEASE; ANIMAL; CALCIUM SIGNALING; GENETICS; HOMEOSTASIS; HUMAN; METABOLISM; NEUROFIBRILLARY TANGLE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SYNAPSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CALCIUM; CALCIUM SIGNALING; HOMEOSTASIS; HUMANS; NEUROFIBRILLARY TANGLES; PRESENILINS; PROTEIN ISOFORMS; SYNAPSES;

EID: 77951951476     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00976.x     Document Type: Review

References (130)

1. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001, 81:741-66.
2. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nature Rev Mol Cell Biol. 2007, 8:101-12.
3. Hardy J, Selkoe DJ. Medicine-The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002, 297:353-6.
4. Alzheimer A. Über eigenartige Krankheitsfälle des späteren Alters. Z ges Neurol Psychiatr. 1911, 4:356-85.
5. Bachman DL, Wolf PA, Linn R. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology. 1992, 42:115-9.
6. Kukull WA, Bowen JD. Dementia epidemiology. Med Clin North Am. 2002, 86:573-90.
7. Evans DA, Funkenstein HH, Albert MS. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA. 1989, 262:2551-6.
8. Cedazo-Minguez A. Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities. J Cell Mol Med. 2007, 11:1227-38.
9. Corder EH, Saunders AM, Strittmatter WJ. Gene dose of apolipoprotein-E type-4 allele and the risk of Alzheimers-disease in late-onset families. Science. 1993, 261:921-3.
10. Haass C. Take five-BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation. EMBO J. 2004, 23:483-8.
11. Steiner H, Haass C. Intramembrane proteolysis by presenilins. Nat Rev Mol Cell Biol. 2000, 1:217-24.
12. Morrissette DA, Parachikova A, Green KN. Relevance of transgenic mouse models to human alzheimer disease. J Biol Chem. 2009, 284:6033-7.
13. Walsh DM, Selkoe DJ. A beta oligomers - a decade of discovery. J Neurochem. 2007, 101:1172-84.
14. Chen YR, Glabe CG. Distinct early folding and aggregation properties of Alzheimer amyloid-beta peptides A beta 40 and A beta 42 - stable trimer or tetramer formation by A beta 42. J Biol Chem. 2006, 281:24414-22.
15. Bliss TV, Lomo T. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J Physiol. 1973, 232:331-56.
16. Walsh DM, Klyubin I, Fadeeva JV. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002, 416:535-9.
17. Shankar GM, Bloodgood BL, Townsend M. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007, 27:2866-75.
18. Lacor PN, Buniel MC, Furlow PW. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci. 2007, 27:796-807.
19. Lacor PN, Buniel MC, Chang L. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci. 2004, 24:10191-200.
20. Shankar GM, Li S, Mehta TH. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008, 14:837-42.
21. Lesne S, Koh MT, Kotilinek L. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006, 440:352-7.
22. Selkoe DJ. Clearing the brain's amyloid cobwebs. Neuron. 2001, 32:177-80.
23. Tanzi RE, Moir RD, Wagner SL. Clearance of Alzheimer's Abeta peptide: the many roads to perdition. Neuron. 2004, 43:605-8.
24. Iwata N, Tsubuki S, Takaki Y. Identification of the major A beta(1-42)-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med. 2000, 6:143-50.
25. Leissring MA, Farris W, Chang AY. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron. 2003, 40:1087-93.
26. Choi DS, Wang D, Yu GQ. PKC epsilon increases endothelin converting enzyme activity and reduces amyloid plaque pathology in transgenic mice. Proc Natl Acad Sci USA. 2006, 103:8215-20.
27. Tucker HM, Kihiko M, Caldwell JN. The plasmin system is induced by and degrades amyloid-beta aggregates. J Neurosci. 2000, 20:3937-46.
28. Mueller-Steiner S, Zhou Y, Arai H. Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron. 2006, 51:703-14.
29. Meilandt WJ, Cisse M, Ho K. Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic A beta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. J Neurosci. 2009, 29:1977-86.
30. Mouri A, Zou LB, Iwata N. Inhibition of neprilysin by thiorphan (i.c.v.) causes an accumulation of amyloid beta and impairment of learning and memory. Behav Brain Res. 2006, 168:83-91.
31. Huang SM, Mouri A, Kokubo H. Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. J Biol Chem. 2006, 281:17941-51.
32. Iwata N, Takaki Y, Fukami S. Region-specific reduction of A beta-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J Neurosci Res. 2002, 70:493-500.
33. Caccamo A, Oddo S, Sugarman MC. Age- and region-dependent alterations in A beta-degrading enzymes: implications for A beta-induced disorders. Neurobiol Aging. 2005, 26:645-54.
34. Hellström-Lindahl E, Ravid R, Nordberg A. Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: inverse correlation with A beta levels. Neurobiol Aging. 2008, 29:210-21.
35. LaFerla FM. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nature Rev Neurosci. 2002, 3:862-72.
36. Khachaturian ZS. Calcium, membranes, aging, and Alzheimer's disease. Introduction and overview. Ann N Y Acad Sci. 1989, 568:1-4.
37. Khachaturian ZS. Calcium hypothesis of Alzheimer's disease and brain aging. Ann N Y Acad Sci. 1994, 747:1-11.
38. Green KN, LaFerla FM. Linking calcium to A beta and Alzheimer's disease. Neuron. 2008, 59:190-4.
39. Arispe N, Rojas E, Pollard HB. Alzheimer-disease amyloid beta-protein forms calcium channels in bilayer-membranes-blockade by tromethamine and aluminum. Proc Natl Acad Sci USA. 1993, 90:567-71.
40. Glabe CG. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging. 2006, 27:570-5.
41. Lee G, Pollard HB, Arispe N. Annexin 5 and apolipoprotein E2 protect against Alzheimer's amyloid-beta-peptide cytotoxicity by competitive inhibition at a common phosphatidylserine interaction site. Peptides. 2002, 23:1249-63.
42. Arispe N, Diaz JC, Simakova O. A beta ion channels. Prospects for treating Alzheimer's disease with A beta channel blockers. Biochim Biophys Acta. 2007, 1768:1952-65.
43. Demuro A, Mina E, Kayed R. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem. 2005, 280:17294-300.
44. De Felice FG, Velasco PT, Lambert MP. Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem. 2007, 282:11590-601.
45. Ueda K, Shinohara S, Yagami T. Amyloid beta protein potentiates Ca2+ influx through L-type voltage-sensitive Ca2+ channels: a possible involvement of free radicals. J Neurochem. 1997, 68:265-71.
46. Nimmrich V, Grimm C, Draguhn A. Amyloid beta oligomers (A beta(1-42) globulomer) suppress spontaneous synaptic activity by inhibition of P/Q-type calcium currents. J Neurosci. 2008, 28:788-97.
47. Liu QS, Kawai H, Berg DK. beta-Amyloid peptide blocks the response of alpha 7-containing nicotinic receptors on hippocampal neurons. Proc Natl Acad Sci USA. 2001, 98:4734-9.
48. Hensley K, Carney JM, Mattson MP. A model for beta-amyloid aggregation and neurotoxicity based on free-radical generation by the peptide - relevance to alzheimer-disease. Proc Natl Acad Sci USA. 1994, 91:3270-4.
49. Mark RJ, Hensley K, Butterfield DA, Mattson MP. Amyloid beta-peptide impairs ion-motive ATPase activities - evidence for a role in loss of neuronal Ca2+ homeostasis and cell-death. J Neurosci. 1995, 15:6239-49.
50. Mark RJ, Pang Z, Geddes JW. Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J Neurosci. 1997, 17:1046-54.
51. Bezprozvanny I, Mattson MP. Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci. 2008, 31:454-63.
52. Leissring MA, Murphy MP, Mead TR. A physiologic signaling role for the gamma -secretase-derived intracellular fragment of APP. Proc Natl Acad Sci USA. 2002, 99:4697-702.
53. Cao X, Südhof TC. A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60. Science. 2001, 293:115-20.
54. Hebert SS, Serneels L, Tolia A. Regulated intramembrane proteolysis of amyloid precursor protein and regulation of expression of putative target genes. EMBO Rep. 2006, 7:739-45.
55. Müller T, Meyer HE, Egensperger R. The amyloid precursor protein intracellular domain (AICD) as modulator of gene expression, apoptosis, and cytoskeletal dynamics-relevance for Alzheimer's disease. Prog Neurobiol. 2008, 85:393-406.
56. Mattson MP, Cheng B, Culwell AR. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron. 1993, 10:243-54.
57. Furukawa K, Barger SW, Blalock EM. Activation of K+ channels and suppression of neuronal activity by secreted beta-amyloid-precursor protein. Nature. 1996, 379:74-8.
58. Querfurth HW, Selkoe DJ. Calcium ionophore increases amyloid-beta peptide production by cultured-cells. Biochemistry. 1994, 33:4550-61.
59. Querfurth HW, Jiang JW, Geiger JD. Caffeine stimulates amyloid beta-peptide release from beta-amyloid precursor protein-transfected HEK293 cells. J Neurochem. 1997, 69:1580-91.
60. Buxbaum JD, Ruefli AA, Parker CA. Calcium regulates processing of the alzheimer amyloid protein-precursor in a protein-kinase C-independent manner. Proc Natl Acad Sci USA. 1994, 91:4489-93.
61. Pierrot N, Ghisdal P, Caumont AS. Intraneuronal amyloid-beta 1-42 production triggered by sustained increase of cytosolic calcium concentration induces neuronal death. J Neurochem. 2004, 88:1140-50.
62. Dreses-Werringloer U, Lambert JC, Vingtdeux V. A polymorphism in CALHM1 influences Ca2+ homeostasis, A beta levels, and Alzheimer's disease risk. Cell. 2008, 133:1149-61.
63. Bertram L, Schjeide BMM, Hooli B. No Association between CALHM1 and Alzheimer's disease risk. Cell. 2008, 135:993-4.
64. Sleegers K, Brouwers N, Bettens K. No association between CALHM1 and risk for Alzheimer dementia in a Belgian population. Hum Mutat 2009, 30:E570-74.
65. Avila J, Perez M, Lim F. Tau in neurodegenerative diseases: tau phosphorylation and assembly. Neurotox Res. 2004, 6:477-82.
66. Stutzmann GE. The pathogenesis of Alzheimers disease - is it a lifelong " Calciumopathy" ?. Neuroscientist. 2007, 13:546-59.
67. Stutzmann GE. Calcium dysregulation, IP3 signaling, and Alzheimer's disease. Neuroscientist. 2005, 11:110-5.
68. Cheung KH, Shineman D, Muller M. Mechanism of Ca2+ disruption in Alzheimer's disease by presenilin regulation of InsP3 receptor channel gating. Neuron. 2008, 58:871-83.
69. Stutzmann GE, Smith I, Caccamo A. Enhanced ryanodine receptor recruitment contributes to Ca2+ disruptions in young, adult, and aged Alzheimer's disease mice. J Neurosci. 2006, 26:5180-9.
70. Rybalchenko V, Hwang SY, Rybalchenko N. The cytosolic N-terminus of presenilin-1 potentiates mouse ryanodine receptor single channel activity. Int J Biochem Cell Biol. 2008, 40:84-97.
71. Hayrapetyan V, Rybalchenko V, Rybalchenko N. The N-terminus of presenilin-2 increases single channel activity of brain ryanodine receptors through direct protein-protein interaction. Cell Calcium. 2008, 44:507-18.
72. Green KN, Demuro A, Akbari Y. SERCA pump activity is physiologically regulated by presenilin and regulates amyloid beta production. J Cell Biol. 2008, 181:1107-16.
73. Ito E, Oka K, Etcheberrigaray R. Internal Ca2+ mobilization is altered in fibroblasts from patients with Alzheimer disease. Proc Natl Acad Sci USA. 1994, 91:534-8.
74. Etcheberrigaray R, Hirashima N, Nee L. Calcium responses in fibroblasts from asymptomatic members of Alzheimer's disease families. Neurobiol Dis. 1998, 5:37-45.
75. Guo Q, Fu W, Sopher BL. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nat Med. 1999, 5:101-6.
76. Leissring MA, Paul BA, Parker I. Alzheimer's presenilin-1 mutation potentiates inositol 1,4,5-trisphosphate-mediated calcium signaling in Xenopus oocytes. J Neurochem. 1999, 72:1061-8.
77. Cedazo-Minguez A, Popescu BO, Ankarcrona M. The presenilin 1 deltaE9 mutation gives enhanced basal phospholipase C activity and a resultant increase in intracellular calcium concentrations. J Biol Chem. 2002, 277:36646-55.
78. Popescu BO, Cedazo-Minguez A, Benedikz E. Gamma-secretase activity of presenilin 1 regulates acetylcholine muscarinic receptor-mediated signal transduction. J Biol Chem. 2004, 279:6455-64.
79. Zhang C, Wu B, Beglopoulos V. Presenilins are essential for regulating neurotransmitter release. Nature. 2009, 460:632-6.
80. Tu H, Nelson O, Bezprozvanny A. Presenilins form ER Ca2+ leak channels, a function disrupted by familial Alzheimer's disease-linked mutations. Cell. 2006, 126:981-93.
81. Nelson O, Tu H, Lei T. Familial Alzheimer disease-linked mutations specifically disrupt Ca2+ leak function of presenilin 1. J Clin Invest. 2007, 117:1230-9.
82. Garaschuk O, Yaari Y, Konnerth A. Release and sequestration of calcium by ryanodine-sensitive stores in rat hippocampal neurones. J Physiol. 1997, 502:13-30.
83. Parekh AB, Putney JW. Store-operated calcium channels. Physiol Rev. 2005, 85:757-810.
84. Parekh AB, Penner R. Store depletion and calcium influx. Physiol Rev. 1997, 77:901-30.
85. Parekh AB. Mitochondrial regulation of intracellular Ca2+ signaling: more than just simple Ca2+ buffers. News Physiol Sci. 2003, 18:252-6.
86. Celsi F, Pizzo P, Brini M. Mitochondria, calcium and cell death: a deadly triad in neurodegeneration. Biochim Biophys Acta. 2009, 1787:335-44.
87. Starkov AA, Beal FM. Portal to Alzheimer's disease. Nat Med. 2008, 14:1020-1.
88. Kuchibhotla KV, Goldman ST, Lattarulo CR. Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron. 2008, 59:214-25.
89. Meyer-Luehmann M, Spires-Jones TL, Prada C. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature. 2008, 451:720-4.
90. Busche MA, Eichhoff G, Adelsberger H. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science. 2008, 321:1686-9.
91. Kuchibhotla KV, Lattarulo CR, Hyman BT. Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice. Science. 2009, 323:1211-5.
92. Takano T, Han X, Deane R. Two-photon imaging of astrocytic Ca2+ signaling and the microvasculature in experimental mice models of Alzheimer's disease. Ann N Y Acad Sci. 2007, 1097:40-50.
93. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002, 298:789-91.
94. Whitehouse PJ, Price DL, Struble RG. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science. 1982, 215:1237-9.
95. Buell SJ, Coleman PD. Dendritic growth in the aged human brain and failure of growth in senile dementia. Science. 1979, 206:854-6.
96. Hamos JE, DeGennaro LJ, Drachman DA. Synaptic loss in Alzheimer's disease and other dementias. Neurology. 1989, 39:355-61.
97. DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol. 1990, 27:457-64.
98. Thal DR, Griffin WS, Braak H. Parenchymal and vascular Abeta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease. J Cell Mol Med. 2008, 12:1848-62.
99. Tsai J, Grutzendler J, Duff K. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci. 2004, 7:1181-3.
100. Moolman DL, Vitolo OV, Vonsattel JP. Dendrite and dendritic spine alterations in Alzheimer models. J Neurocytol. 2004, 33:377-87.
101. Spires TL, Meyer-Luehmann M, Stern EA. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci. 2005, 25:7278-87.
102. Koffie RM, Meyer-Luehmann M, Hashimoto T. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci USA. 2009, 106:4012-7.
103. Kamenetz F, Tomita T, Hsieh H. APP processing and synaptic function. Neuron. 2003, 37:925-37.
104. Hsieh H, Boehm J, Sato C. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron. 2006, 52:831-43.
105. Snyder EM, Nong Y, Almeida CG. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci. 2005, 8:1051-8.
106. Chang EH, Savage MJ, Flood DG. AMPA receptor downscaling at the onset of Alzheimer's disease pathology in double knockin mice. Proc Natl Acad Sci USA. 2006, 103:3410-5.
107. Oddo S, Caccamo A, Shepherd JD. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003, 39:409-21.
108. Palop JJ, Chin J, Roberson ED. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 2007, 55:697-711.
109. Palop JJ, Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol. 2009, 66:435-40.
110. Minkeviciene R, Rheims S, Dobszay MB. Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci. 2009, 29:3453-62.
111. Phinney AL, Deller T, Stalder M. Cerebral amyloid induces aberrant axonal sprouting and ectopic terminal formation in amyloid precursor protein transgenic mice. J Neurosci. 1999, 19:8552-9.
112. Sturchler-Pierrat C, Abramowski D, Duke M. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA. 1997, 94:13287-92.
113. Cirrito JR, Kang JE, Lee J. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron. 2008, 58:42-51.
114. Mendez M, Lim G. Seizures in elderly patients with dementia: epidemiology and management. Drug Aging. 2003, 20:791-803.
115. Snider BJ, Norton J, Coats MA. Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life. Arch Neurol. 2005, 62:1821-30.
116. Menendez M. Down syndrome, Alzheimer's disease and seizures. Brain Dev. 2005, 27:246-52.
117. Ponomareva NV, Korovaitseva GI, Rogaev EI. EEG alterations in non-demented individuals related to apolipoprotein E genotype and to risk of Alzheimer disease. Neurobiol Aging. 2008, 29:819-27.
118. Sperling RA, Laviolette PS, O'Keefe K. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron. 2009, 63:178-88.
119. Arriagada PV, Marzloff K, Hyman BT. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology. 1992, 42:1681-8.
120. Crystal HA, Dickson DW, Sliwinski MJ. Pathological markers associated with normal aging and dementia in the elderly. Ann Neurol. 1993, 34:566-73.
121. Naslund J, Haroutunian V, Mohs R. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA. 2000, 283:1571-7.
122. Lue LF, Kuo YM, Roher AE. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol. 1999, 155:853-62.
123. Koistinaho M, Ort M, Cimadevilla JM. Specific spatial learning deficits become severe with age in beta -amyloid precursor protein transgenic mice that harbor diffuse beta -amyloid deposits but do not form plaques. Proc Natl Acad Sci USA. 2001, 98:14675-80.
124. Westerman MA, Cooper-Blacketer D, Mariash A. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci. 2002, 22:1858-67.
125. Itagaki S, McGeer PL, Akiyama H. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol. 1989, 24:173-82.
126. Wegiel J, Wisniewski HM. The complex of microglial cells and amyloid star in three-dimensional reconstruction. Acta Neuropathol. 1990, 81:116-24.
127. Streit WJ. Microglia and Alzheimer's disease pathogenesis. J Neurosci Res. 2004, 77:1-8.
128. Alexander C, Rietschel ET. Bacterial lipopolysaccharides and innate immunity. J Endotoxin Res. 2001, 7:167-202.
129. Rodgers KM, Hutchinson MR, Northcutt A. The cortical innate immune response increases local neuronal excitability leading to seizures. Brain. 2009, 132:2478-86.
130. Airaksinen MS, Eilers J, Garaschuk O. Ataxia and altered dendritic calcium signaling in mice carrying a targeted null mutation of the calbindin D28k gene. Proc Natl Acad Sci USA. 1997, 94:1488-93.